Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
5.
Pathologe ; 41(4): 406-410, 2020 Jul.
Article in German | MEDLINE | ID: mdl-32472158

ABSTRACT

Proliferative changes seen in reactive mesothelial hyperplasia of a hydrocele sac may mimic malignant mesothelioma. There is no immunohistochemical staining that reliably separates benign from malignant mesothelial proliferations. However, the combined analysis of BAP1 by immunohistochemistry and CDKN2A by FISH has been reported to yield both a high specificity and sensitivity in this differential diagnosis. In addition, the evaluation of risk factors such as asbestos exposure or prior traumata may be helpful for the correct diagnosis. Exclusion of stromal invasion, which is diagnostic for malign mesothelioma, is of utmost importance. Therefore, extended histological workup is essential.


Subject(s)
Lung Neoplasms , Mesothelioma , Testicular Neoplasms , Cell Proliferation , Diagnosis, Differential , Humans , Immunohistochemistry , Lung Neoplasms/diagnosis , Male , Mesothelioma/diagnosis , Testicular Neoplasms/pathology , Testis , Tumor Suppressor Proteins/analysis , Ubiquitin Thiolesterase/analysis
6.
Pathologe ; 34(4): 305-9, 2013 Jul.
Article in German | MEDLINE | ID: mdl-23503854

ABSTRACT

BACKGROUND: Definitive diagnosis of unclear pulmonary lesions is mainly based on morphological methods. In addition to a neoplasm, inflammatory reactions, in particular tuberculosis (TB), have to be considered in most cases. Therefore, the aim of this work was to determine whether established methods used in general pathology can be efficiently used with cytological material. MATERIALS AND METHODS: An established polymerase chain reaction (PCR) protocol for the detection of Mycobacterium tuberculosis complex (Mtc) DNA in fixed specimens was conducted on fixed material available as an assay for liquid-based cytology (LBC). CytoLyt®-fixed material of 45 patients with clinically suspected TB or other mycobacteriosis were selected and were initially tested cytologically. In cases of absent tumor cells, PCR for detection of Mtc DNA and Ziehl-Neelsen stain (ZN) were performed. RESULTS: In 9 patients (20 %), Mtc DNA was found by PCR. The following methods were used to obtain material: catheter biopsy (5), needle biopsy (2), transbronchial needle aspiration (1), and bronchoalveolar lavage (1). Cytologically an inflammatory reaction was observed in all cases. In 2 patients, a history of TB, in 2 further cases either silicosis or a posttransplant situation was known. In cases with a positive PCR, 7 patients (78 %) were positive in ZN and 3 patients (33.3 %) in TB culture (15.5 % vs. 6.7 % of the total cohort); however, the material used for investigation was not always from identical sources, respectively. In 36 out of 45 patients, both PCR and ZN were negative for the detection of Mtc DNA. CONCLUSION: The material intended for LBC can be used for detection of TB with ZN and Mtc PCR.


Subject(s)
Coloring Agents , Polymerase Chain Reaction/methods , Tuberculosis, Pulmonary/pathology , Adult , Aged , Aged, 80 and over , Bacteriological Techniques , Biopsy , DNA, Bacterial/analysis , DNA, Bacterial/genetics , Diagnosis, Differential , Female , Humans , Lung/pathology , Male , Middle Aged , Mycobacterium tuberculosis/genetics , Predictive Value of Tests , Tuberculosis, Pulmonary/microbiology
7.
Pathologe ; 34(2): 94-104, 2013 Mar.
Article in German | MEDLINE | ID: mdl-23423505

ABSTRACT

Esophageal malformations are rare and can occur sporadically or as a component of various syndromes. The variations and classifications are manifold. With the available modern operation techniques most malformations can be resolved with good results. However, esophageal malformations are often combined with further malformations which limit the prognosis. The separation of the trachea and esophagus after gastrulation is not yet completely researched. The results so far indicate that the localized expression of various homeodomain transcription factors is essential for normal development of the trachea and esophagus.


Subject(s)
Esophagus/abnormalities , Esophagus/pathology , Anastomosis, Surgical , Diseases in Twins/diagnosis , Diseases in Twins/genetics , Diseases in Twins/pathology , Diseases in Twins/surgery , Diverticulum, Esophageal/diagnosis , Diverticulum, Esophageal/genetics , Diverticulum, Esophageal/pathology , Diverticulum, Esophageal/surgery , Esophageal Atresia/diagnosis , Esophageal Atresia/genetics , Esophageal Atresia/pathology , Esophageal Atresia/surgery , Esophagus/embryology , Esophagus/surgery , Female , Genetic Loci/genetics , Humans , Infant , Infant, Newborn , Male , Phenotype , Prognosis , Syndrome , Trachea/abnormalities , Trachea/embryology , Trachea/pathology , Trachea/surgery , Tracheoesophageal Fistula/diagnosis , Tracheoesophageal Fistula/genetics , Tracheoesophageal Fistula/pathology , Tracheoesophageal Fistula/surgery
8.
Pathologe ; 34(4): 338-42, 2013 Jul.
Article in German | MEDLINE | ID: mdl-23263441

ABSTRACT

Benign epithelial tumors of the tracheobronchial system and the lungs are exceedingly rare. These entities encompass squamous and glandular papillomas (as well as their mixed forms) and adenomas (alveolar adenoma, papillary adenoma, salivary gland-like pleomorphic and mucinous adenomas and mucinous cystadenomas). These tumors are considered to be biologically benign neoplasms; however, they can pose considerable diagnostic difficulties, especially during frozen section evaluation, as they can mimic malignant tumors and in particular they can resemble well differentiated papillary adenocarcinomas. As a result of the extreme rarity of these tumors only a few descriptive diagnostic series exist and a systematic investigation including molecular data does not exist. This article presents the case of a 64-year-old patient with a glandular papilloma of the right main bronchus including the immunohistochemical and molecular work-up as well as a review of the current literature.


Subject(s)
Bronchial Neoplasms/genetics , Bronchial Neoplasms/pathology , Exons/genetics , Mutation/genetics , Papilloma/genetics , Proto-Oncogene Proteins/genetics , ras Proteins/genetics , Adenocarcinoma, Papillary/genetics , Adenocarcinoma, Papillary/pathology , Amino Acid Substitution/genetics , Asparagine/genetics , Bronchi/pathology , Bronchi/surgery , Bronchial Neoplasms/surgery , Bronchoscopy , Diagnosis, Differential , ErbB Receptors/genetics , Female , Frozen Sections , Glycine/genetics , Humans , Middle Aged , Papilloma/pathology , Papilloma/surgery , Pneumonectomy , Proto-Oncogene Proteins p21(ras) , Sequence Analysis, DNA , Tumor Suppressor Protein p53/genetics
9.
Pathologe ; 33(4): 308-15, 2012 Jul.
Article in German | MEDLINE | ID: mdl-22752354

ABSTRACT

Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TBNA) has become an important tool in the diagnosis and staging of malignant tumors of the lungs and mediastinum. Rapid on-site evaluation (ROSE) denotes a cytomorphological diagnostic procedure that allows assessment of the adequacy and accuracy of the material obtained during bronchoscopy within a few minutes in or near the bronchoscopy suite (on-site) using a quick staining of smears. This results in a significant decrease in the number of repeated bronchoscopy procedures required to recover an adequate biopsy sample and is therefore both time and cost effective. The obtained material can be further assessed as conventional cytological specimens or alternatively using the thin-prep technique for definitive cytopathology diagnosis and/or embedded in paraffin for immunohistochemical or molecular analyses such as DNA sequencing or flow cytometry.


Subject(s)
Lung Neoplasms/pathology , Mediastinal Neoplasms/pathology , Algorithms , Biopsy, Fine-Needle/instrumentation , Biopsy, Needle , Bronchoscopy/instrumentation , Cytological Techniques/methods , Equipment Design , Humans , Lung/pathology , Lung Neoplasms/diagnostic imaging , Lymphatic Metastasis/pathology , Mediastinal Neoplasms/diagnostic imaging , Mediastinoscopy , Neoplasm Staging , Predictive Value of Tests , Time and Motion Studies , Tomography, X-Ray Computed , Ultrasonography, Interventional/instrumentation
10.
Pathologe ; 33(3): 175-82, 2012 May.
Article in German | MEDLINE | ID: mdl-22576594

ABSTRACT

Left ventricular assist devices (LVAD) are currently used to treat patients with terminal congestive heart failure as a bridge to transplantation or as destination therapy in individuals with contraindications for cardiac transplantation. The LVADs are pulsatile or non-pulsatile systems that transport blood from the left ventricle to the ascending aorta parallel to the circulation thus providing a profound volume and pressure reduction in the left ventricle. The use of LVADs is associated with a considerable decrease of cardiac hypertrophy and dilation with significantly improved cardiac performance in a small subset of patients. The underlying process is termed reverse cardiac remodelling and is characterized by a significant decrease in the size of cardiomyocytes and reversible regulation of numerous molecular systems in the myocardium.


Subject(s)
Heart Failure/pathology , Heart Failure/therapy , Heart-Assist Devices , Myocardium/pathology , Regeneration/physiology , Blood Pressure/physiology , Blood Volume/physiology , Cell Size , DNA Replication/physiology , Extracellular Matrix/physiology , Humans , Inflammation Mediators/physiology , Myocytes, Cardiac/pathology , Natriuretic Peptides/physiology , Proteasome Endopeptidase Complex/physiology , Receptors, Adrenergic, beta/physiology , Renin-Angiotensin System/physiology , Signal Transduction/physiology , Stem Cells/pathology , Ubiquitin/physiology
12.
Pathologe ; 32(2): 104-12, 2011 Mar.
Article in German | MEDLINE | ID: mdl-21424408

ABSTRACT

Lung transplantation is the ultimate therapeutical approach for the treatment of both children and adults with terminal congenital or acquired lung disease. In contrast to survival rates during the first year following transplantation, the long-term survival for patients after lung transplantation has not significantly improved in the past. In addition to other complications, acute cellular rejection constitutes a major cause for diminished function of pulmonary grafts, and can, among other factors, be causative for chronic rejection (bronchiolitis obliterans syndrome, BOS). In 2006, the International Society for Heart and Lung Transplantation (ISHLT) provided a revised version of the grading system for acute and chronic rejection of pulmonary grafts.


Subject(s)
Graft Rejection/pathology , Lung Transplantation/pathology , Adult , Biopsy , Bronchiolitis Obliterans/classification , Bronchiolitis Obliterans/immunology , Bronchiolitis Obliterans/mortality , Bronchiolitis Obliterans/pathology , Child , Graft Rejection/classification , Graft Rejection/immunology , Graft Rejection/mortality , Histocompatibility Testing , Humans , Immunity, Cellular/immunology , Immunosuppressive Agents/therapeutic use , Leukocytes/immunology , Leukocytes/pathology , Lung/immunology , Lung/pathology , Lung Transplantation/immunology , Prognosis , Risk Factors , Survival Rate , Transplantation Immunology/immunology
13.
Pathologe ; 32(2): 95-103, 2011 Mar.
Article in German | MEDLINE | ID: mdl-21305380

ABSTRACT

Since the first heart transplantation in 1967, the procedure has become an established therapy in the treatment of terminal heart failure. Constant advances in the development of potent immunosuppressive drugs, as well as greater clinical experience and pathological diagnostics have improved patient survival dramatically. The first grading system for rejection was published in 1990 by the International Society for Heart and Lung Transplantation (ISHLT) and revised in 2004. The 2004 grading system comprises three grades of severity (1R, 2R, 3R), whereby the former grade 2 in the 1990 system has been incorporated in the new grade 1R. Recommendations are made for the histological diagnosis of acute antibody-mediated rejection using immunohistochemical staining against C4d and macrophages. To the present day, the pathological examination of endomyocardial biopsies remains the gold standard for post-transplant diagnostic procedures. Whether or not non-invasive diagnostic approaches (e.g. gene array profile analysis on leukocytes) can replace morphological investigations needs to be clarified in randomised, prospective clinical studies.


Subject(s)
Graft Rejection/pathology , Heart Failure/surgery , Heart Transplantation/pathology , Biopsy , Endocardium/immunology , Endocardium/pathology , Endothelium, Vascular/immunology , Endothelium, Vascular/pathology , Eosinophils/immunology , Eosinophils/pathology , Graft Rejection/classification , Graft Rejection/immunology , Heart Failure/pathology , Heart Transplantation/immunology , Humans , Immunity, Cellular/immunology , Lymphocytes/immunology , Lymphocytes/pathology , Myocardium/immunology , Myocardium/pathology , Myocytes, Cardiac/immunology , Myocytes, Cardiac/pathology , Plasma Cells/immunology , Plasma Cells/pathology , Transplantation Immunology/immunology
14.
Pathologe ; 31(5): 355-60, 2010 Sep.
Article in German | MEDLINE | ID: mdl-20809404

ABSTRACT

The staging system for lung tumours is now recommended for the classification of both non-small-cell and small-cell lung cancer as well as for carcinoid tumours of the lung. The T classifications have been redefined: T1 has been subclassified as T1a (≤ 2 cm in size) and T1b (> 2-3 cm in size). T2 has been subclassified as T2a (> 3-5 cm in size) and T2b (> 5-7 cm in size). T2 (> 7 cm in size) has been reclassified as T3. Multiple tumour nodules in the same lobe have been reclassified from T4 to T3. Multiple tumour nodules in the same lung but a different lobe have been reclassified from M1 to T4. No changes have been made in the N classification. The M classification has been redefined: M1 has been subdivided into M1a and M1b. Malignant pleural and pericardial effusions have been reclassified from T4 to M1a. Separate tumour nodules in the contralateral lung have been reclassified from T4 to M1a. M1b designates distant metastasis.


Subject(s)
Carcinoid Tumor/pathology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/pathology , Lung Neoplasms/pathology , Neoplasm Staging/methods , Carcinoid Tumor/classification , Carcinoma, Non-Small-Cell Lung/classification , Carcinoma, Small Cell/classification , Disease Progression , Humans , Lung/pathology , Lung Neoplasms/classification , Lymphatic Metastasis/pathology , Neoplasm Invasiveness/pathology , Neoplasms, Multiple Primary/classification , Neoplasms, Multiple Primary/pathology , Pleural Effusion, Malignant/pathology
15.
Article in English | MEDLINE | ID: mdl-17409785

ABSTRACT

Cholesteatomas show histomorphological features like papillary growth and koilocytosis, which are characteristic of lesions induced by human papillomaviruses (HPV). Two previous studies investigating the possible role of HPV in the development of cholesteatoma had detected HPV-6 and HPV-11 DNA with a prevalence differing from 3 to 36%. The aim of the presented study was to evaluate the prevalence of different HPV types in cholesteatomas using a sensitive detection system for HPV DNA. Twenty-nine biopsies from cholesteatomas were screened for HPV DNA with a 2-step broad-spectrum PCR (PCR and nested PCR). HPV-positive products were directly sequenced by means of a cycle sequencing approach. Sensitivity of the applied broad-spectrum PCR was 0.1 copy/genome. One out of 29 biopsies showed a positive signal on the nested PCR level. Considering the low prevalence (1/29 biopsies) of detected HPV DNA in cholesteatomas, infections with common HPV types are unlikely to be a causative factor.


Subject(s)
Cholesteatoma, Middle Ear , Papillomavirus Infections , Adolescent , Adult , Aged , Child , Cholesteatoma, Middle Ear/epidemiology , Cholesteatoma, Middle Ear/genetics , Cholesteatoma, Middle Ear/virology , DNA Primers/genetics , DNA, Viral/genetics , Female , Humans , Male , Middle Aged , Papillomavirus Infections/epidemiology , Papillomavirus Infections/genetics , Papillomavirus Infections/virology , Polymerase Chain Reaction , Prevalence
16.
Histopathology ; 46(1): 89-97, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15656891

ABSTRACT

AIMS: Eosinophilic heart syndromes are rare in Western countries and include endocarditis parietalis fibroplastica (EPF) and hypersensitivity myocarditis (HM). There are striking differences in natural history and morphological findings. Since diagnosis can be difficult when analysing small myocardial biopsies lacking the characteristic histological features, we studied a set of immunohistochemical markers in order to characterize the activation status of the infiltrating eosinophils to distinguish between these two entities. METHODS AND RESULTS: This study is based on the investigation of seven explanted hearts and one left ventricular specimen collected during implantation of a left ventricular assist device from a total of seven patients with HM. Also investigated were three right and three left ventricular specimens from five patients with EPF. We used antibodies (Ab) against EG1, and EG2, CD44, and CD69 which have been described as markers to distinguish between resting and activated eosinophils. The EG1 to EG2 ratio of eosinophils and the immunoreactivity against CD44 showed no differences between the two entities. However, eosinophils in the EPF were completely negative for CD69, whereas eosinophils reacted positively within the HM group. CONCLUSION: The immunohistochemical investigation of eosinophilic heart diseases using antibodies against CD69 can be a useful tool to distinguish between hypersensitivity myocarditis and endocarditis parietalis fibroplastica.


Subject(s)
Eosinophils/immunology , Heart Diseases/immunology , Immunohistochemistry , Aged , Animals , Antibodies, Monoclonal/immunology , Antigens, CD/immunology , Antigens, Differentiation, T-Lymphocyte/immunology , Diagnosis, Differential , Endocarditis/diagnosis , Endocarditis/immunology , Endocarditis/pathology , Eosinophils/pathology , Female , Heart Diseases/diagnosis , Heart Diseases/pathology , Humans , Lectins, C-Type , Male , Mice , Middle Aged , Myocarditis/diagnosis , Myocarditis/immunology , Myocarditis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL